Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.
- Term
- 16 weeks
“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus